Therapeutic profile of patients with diabetes treated at the first level of health care

Autores
Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; Marin, Gina; Vera, Zully; Lugo Rodríguez, Gladys B.
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.
Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay
Fil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; Paraguay
Materia
DIABETES
FIRST LEVEL
HEALTH CARE
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/144918
Acceder
id CONICETDig_311101495662d2c2af42c9d3bf8d9b1f
oai_identifier_str oai:ri.conicet.gov.ar:11336/144918
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Therapeutic profile of patients with diabetes treated at the first level of health careMaidana, Gladys MabelMarin, Gustavo HoracioSamaniego, LourdesMarin, LupeMontiel, Dalva FariñaMarin, GinaVera, ZullyLugo Rodríguez, Gladys B.DIABETESFIRST LEVELHEALTH CARETREATMENThttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; ParaguayFil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Samaniego, Lourdes. Universidad Nacional de Asunción; ParaguayFil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; ParaguayFil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; ArgentinaFil: Vera, Zully. Universidad Nacional de Asunción; ParaguayFil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; ParaguayAsclepius2020-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/144918Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-52639-8605CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://asclepiusopen.com/asclepius-medical-research-and-reviews/volume-3-issue-2/1info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:18:01Zoai:ri.conicet.gov.ar:11336/144918instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:18:01.541CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Therapeutic profile of patients with diabetes treated at the first level of health care
title Therapeutic profile of patients with diabetes treated at the first level of health care
spellingShingle Therapeutic profile of patients with diabetes treated at the first level of health care
Maidana, Gladys Mabel
DIABETES
FIRST LEVEL
HEALTH CARE
TREATMENT
title_short Therapeutic profile of patients with diabetes treated at the first level of health care
title_full Therapeutic profile of patients with diabetes treated at the first level of health care
title_fullStr Therapeutic profile of patients with diabetes treated at the first level of health care
title_full_unstemmed Therapeutic profile of patients with diabetes treated at the first level of health care
title_sort Therapeutic profile of patients with diabetes treated at the first level of health care
dc.creator.none.fl_str_mv Maidana, Gladys Mabel
Marin, Gustavo Horacio
Samaniego, Lourdes
Marin, Lupe
Montiel, Dalva Fariña
Marin, Gina
Vera, Zully
Lugo Rodríguez, Gladys B.
author Maidana, Gladys Mabel
author_facet Maidana, Gladys Mabel
Marin, Gustavo Horacio
Samaniego, Lourdes
Marin, Lupe
Montiel, Dalva Fariña
Marin, Gina
Vera, Zully
Lugo Rodríguez, Gladys B.
author_role author
author2 Marin, Gustavo Horacio
Samaniego, Lourdes
Marin, Lupe
Montiel, Dalva Fariña
Marin, Gina
Vera, Zully
Lugo Rodríguez, Gladys B.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv DIABETES
FIRST LEVEL
HEALTH CARE
TREATMENT
topic DIABETES
FIRST LEVEL
HEALTH CARE
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.
Fil: Maidana, Gladys Mabel. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Samaniego, Lourdes. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Lupe. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Montiel, Dalva Fariña. Universidad Nacional de Asunción; Paraguay
Fil: Marin, Gina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas; Argentina
Fil: Vera, Zully. Universidad Nacional de Asunción; Paraguay
Fil: Lugo Rodríguez, Gladys B.. Universidad Nacional de Asunción; Paraguay
description Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. Objective: The aim of this study is to evaluate the therapeutic profile for DM2 in the first level of care in the health system in two different countries (Argentina and Paraguay). Methods: This study was an observational descriptive cross-section study. Variables considered were age, sex, date of disease debut, clinical signs of diabetes complications, blood pressure, abdominal circumference, anti-diabetic and anti-hypertensive drugs, and laboratory data. Results: Regarding medication, 30.6% of the patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.
publishDate 2020
dc.date.none.fl_str_mv 2020-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/144918
Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-5
2639-8605
CONICET Digital
CONICET
url http://hdl.handle.net/11336/144918
identifier_str_mv Maidana, Gladys Mabel; Marin, Gustavo Horacio; Samaniego, Lourdes; Marin, Lupe; Montiel, Dalva Fariña; et al.; Therapeutic profile of patients with diabetes treated at the first level of health care; Asclepius; Asclepius Medical Research and Reviews; 3; 2; 8-2020; 1-5
2639-8605
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://asclepiusopen.com/asclepius-medical-research-and-reviews/volume-3-issue-2/1
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Asclepius
publisher.none.fl_str_mv Asclepius
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614138088652800
score 13.069144

Publicaciones similares